Home › Funds › THIRD AVENUE MANAGEMENT LLC › SUPN

THIRD AVENUE MANAGEMENT LLC position in SUPN

SUPERNUS PHARMACEUTICALS · Health Care

THIRD AVENUE MANAGEMENT LLC reported holding 157,150 shares of SUPN (SUPERNUS PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$6.8M, representing 1.14% of its reported portfolio and ranking #27 among its reported holdings. THIRD AVENUE MANAGEMENT LLC has disclosed SUPN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)157.15K sh
Reported value held$6.76M
Portfolio Weight1.14%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How THIRD AVENUE MANAGEMENT LLC's SUPN position evolved

THIRD AVENUE MANAGEMENT LLC first disclosed a stake in SUPN in Q3 2023 at 116,549 shares (US$3.3M). The position peaked in Q4 2025 at 189,493 shares, worth US$9.4M. Across 13 filings, THIRD AVENUE MANAGEMENT LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 8 time(s). The most recent filing (Q3 2026) shows 157,150 shares valued at US$6.8M — an increase of 4,426 shares quarter over quarter.. Notable position changes include a 37% increase in Q4 2023 (shares rose 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 116.55K $3.27M New
Q4 2023 159.72K $4.62M Add
Q1 2024 159.72K $5.45M Hold
Q2 2024 189.12K $5.06M Add
Q3 2024 189.49K $5.91M Hold
Q4 2024 189.49K $6.85M Hold
Q1 2025 189.49K $6.21M Hold
Q2 2025 189.49K $5.97M Hold
Q3 2025 189.49K $9.10M Hold
Q4 2025 189.49K $9.42M Hold
Q1 2026 152.72K $7.89M Reduce
Q2 2026 152.72K $7.10M Hold
Q3 2026 157.15K $6.76M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SUPN and 13F data

SUPN (SUPERNUS PHARMACEUTICALS) is a Health Care company. 34 other funds we track also report a position in SUPN — the largest reported positions include MILLENNIUM MANAGEMENT LLC (US$179.2M), ARMISTICE CAPITAL, LLC (US$123.1M), Sofinnova Investments, Inc. (US$48.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SUPN

All SUPN fund holders →

FAQ

How long has THIRD AVENUE MANAGEMENT LLC held SUPN?

THIRD AVENUE MANAGEMENT LLC has disclosed SUPN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is THIRD AVENUE MANAGEMENT LLC's current position in SUPN?

As of Q3 2026, THIRD AVENUE MANAGEMENT LLC holds 157.15K shares of SUPN (SUPERNUS PHARMACEUTICALS), valued at $6.76M, representing 1.14% of its reported portfolio and ranking #27.

Has THIRD AVENUE MANAGEMENT LLC been buying or selling SUPN?

In the latest 13F filing (Q3 2026), THIRD AVENUE MANAGEMENT LLC increased its position in SUPN. The position peaked in Q4 2025 at 189.49K shares.

Which other funds hold SUPN?

Other major institutional holders of SUPN include MILLENNIUM MANAGEMENT LLC, ARMISTICE CAPITAL, LLC, Sofinnova Investments, Inc., among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.